| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
Aug 14, 2026 | BUY |
Strong Buy
+4.4% avg upside
36 analysts
|
$125.00
12.38% Upside
|
· | · |
|
SGHT
Sight Sciences
|
Aug 14, 2026 | HOLD |
Buy
+11.9% avg upside
13 analysts
|
$8.00
3.86% Downside
|
+0.0% | · |
|
GKOS
Glaukos
|
Aug 14, 2026 | BUY |
Strong Buy
-10.8% avg upside
21 analysts
|
$225.00
18.81% Upside
|
+0.0% | · |
|
TNDM
Tandem Diabetes Care
|
Aug 14, 2026 | HOLD |
Buy
+41.5% avg upside
29 analysts
|
$24.00
3.85% Upside
|
+0.0% | · |
|
SYK
Stryker
|
Aug 14, 2026 | BUY |
Strong Buy
+8.2% avg upside
37 analysts
|
$399.00
17.04% Upside
|
· | · |
|
DXCM
Dexcom
|
Aug 14, 2026 | BUY |
Strong Buy
+16.1% avg upside
32 analysts
|
$105.00
14.81% Upside
|
+0.0% | · |
|
COO
Cooper Co
|
Aug 14, 2026 | HOLD |
Buy
+74.2% avg upside
21 analysts
|
$80.00
4.54% Upside
|
+0.0% | · |
|
BDX
Becton Dickinson
|
Aug 14, 2026 | BUY |
Buy
+7.8% avg upside
25 analysts
|
$208.00
14.39% Upside
|
· | · |
|
ISRG
Intuitive Surgical
|
Aug 13, 2026 | BUY |
Strong Buy
+19.8% avg upside
36 analysts
|
$500.00
24.60% Upside
|
-1.7% | · |
|
BAX
Baxter International
|
Aug 13, 2026 | HOLD |
Buy
+23.8% avg upside
23 analysts
|
$28.00
3.46% Upside
|
+0.0% | · |
|
BSX
Boston Scientific
|
Aug 13, 2026 | BUY |
Strong Buy
+31.1% avg upside
38 analysts
|
$61.00
17.96% Upside
|
· | · |
|
EW
Edwards Lifesciences
|
Aug 13, 2026 | BUY |
Strong Buy
+8.5% avg upside
34 analysts
|
$110.00
18.87% Upside
|
-1.0% | · |
|
HAE
Haemonetics
|
Aug 13, 2026 | HOLD |
Buy
-15.1% avg upside
18 analysts
|
$92.00
1.72% Upside
|
· | · |
|
PODD
Insulet
|
Aug 13, 2026 | HOLD |
Strong Buy
+48.7% avg upside
32 analysts
|
$150.00
2.50% Upside
|
-2.1% | · |
|
IART
Integra Lifesciences
|
Aug 13, 2026 | HOLD |
Buy
+139.3% avg upside
21 analysts
|
$19.00
4.15% Upside
|
+0.0% | · |
|
JNJ
Johnson & Johnson
|
Aug 13, 2026 | BUY |
Strong Buy
-9.2% avg upside
39 analysts
|
$298.00
13.64% Upside
|
-0.7% | · |
|
MDT
Medtronic
|
Aug 13, 2026 | BUY |
Buy
+6.4% avg upside
38 analysts
|
$110.00
21.35% Upside
|
+1.3% | · |
|
ZBH
Zimmer Biomet Holdings
|
Aug 13, 2026 | HOLD |
Buy
+15.1% avg upside
38 analysts
|
$99.00
0.65% Downside
|
+1.1% | · |
|
IRTC
Irhythm Technologies
|
Aug 13, 2026 | BUY |
Strong Buy
+35.2% avg upside
20 analysts
|
$157.00
27.53% Upside
|
+2.7% | · |
|
ESTA
Establishment Labs Holdings
|
Aug 13, 2026 | BUY |
Strong Buy
+20.3% avg upside
12 analysts
|
$92.00
21.65% Upside
|
+5.1% | · |
|
BLCO
Bausch + Lomb Corporation
|
Aug 13, 2026 | BUY |
Buy
+17.5% avg upside
19 analysts
|
$21.00
23.65% Upside
|
+0.4% | · |
|
GEHC
GE Healthcare Technologies Inc
|
Aug 13, 2026 | HOLD |
Strong Buy
+11.5% avg upside
22 analysts
|
$75.00
1.55% Upside
|
-0.1% | · |
|
WAT
Waters
|
Aug 10, 2026 | BUY |
Strong Buy
-5.0% avg upside
31 analysts
|
$470.00
13.70% Upside
|
+0.4% | · |
|
WST
West Pharmaceutical Services
|
Aug 03, 2026 | BUY |
Strong Buy
+5.7% avg upside
18 analysts
|
$412.00
19.04% Upside
|
-0.5% | · |
|
MMED
MiniMed Group, Inc.
|
Jul 17, 2026 | BUY |
Strong Buy
+10.7% avg upside
14 analysts
|
— | +15.8% | · |
|
ITGR
Integer Holdings
|
Jul 08, 2026 | HOLD |
Buy
-18.1% avg upside
16 analysts
|
$96.00
23.22% Downside
|
+37.4% | · |
|
PEN
Penumbra
|
Jul 08, 2026 | HOLD |
Buy
+1.1% avg upside
23 analysts
|
$350.00
7.07% Upside
|
+3.1% | · |
|
LUNG
Pulmonx
|
May 23, 2025 | HOLD |
Buy
+236.5% avg upside
9 analysts
|
$4.15
92.21% Upside
|
-50.2% | · |
|
CH:ALC
Alcon
|
Nov 16, 2022 | HOLD |
Strong Buy
+19.2% avg upside
35 analysts
|
$56.17
7.23% Downside
|
+1.5% | · |
|
RMD
Resmed
|
Jan 27, 2019 | BUY |
Buy
+1.2% avg upside
27 analysts
|
$120.00
47.15% Downside
|
+77.7% | · |
|
PFE
Pfizer
|
Sep 26, 2016 | BUY |
Buy
+25.4% avg upside
45 analysts
|
$40.00
49.20% Upside
|
+9.2% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.